Réf :HematoStat.net ; 2 (1) : V37 Jenny Klintmanand al.Bone mineral density in haemophilia – a multicentre study evaluating the impact of different replacement regimens. Haemophilia. 2022 Jan 7.  doi: […]

Réf :HematoStat.net ; 1 (12) : V36 Courtney D DiNardoand al.Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia.  J Clin Oncol. […]

Réf :HematoStat.net ; 1 (12) : V35  Thomas Heinickeand al. Allogeneic hematopoietic stem cell transplantation improves long-term outcome for relapsed AML patients across all ages: results from two East German […]

Réf :HematoStat.net ; 1 (12) : V34 Farhad Ravandiand al. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 […]

Réf :HematoStat.net ; 1 (12) : V33 Courtney D DiNardo and al. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, […]

Réf :HematoStat.net ; 1 (12) : V32 Michael Heuserand al. 2021 Update Measurable Residual Disease in Acute Myeloid Leukemia: European LeukemiaNet Working Party Consensus Document. Blood. 2021 Dec 30;138(26):2753-2767. doi: […]

Réf :HematoStat.net ; 1 (12) : V31 Evan M Cherryand al. Venetoclax and Azacitidine Compared to Induction Chemotherapy for Newly Diagnosed Patients with Acute Myeloid Leukemia. Blood Adv. 2021 Dec […]

Réf :HematoStat.net ; 1 (12) : V30 Felicitas Tholand al.Treatment for Relapsed/Refractory Acute Myeloid Leukemia.Hemasphere. 2021 Jun 1;5(6):e572. Doi : 10.1097/HS9.0000000000000572.  

Réf :HematoStat.net ; 1 (11) : V29 Albiol N, Moreno C. Autoimmune Cytopenia in CLL: Prognosis and Management in the Era of Targeted Therapies. Cancer J. 2021 Jul-Aug 01;27(4):286-296. doi: […]

Réf :HematoStat.net ; 1 (11) : V28 Van Gelder M, Tournilhac O, Te Raa D, Visser HPJ. Front-line chemo- immunotherapy is not inferior to ibrutinib in CLL. Ann Oncol. 2021 […]